Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Volume: 380, Issue: 4, Pages: 347 - 357
Published: Jan 24, 2019
Abstract
Background The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium–glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined. Methods We randomly assigned patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease to receive either dapagliflozin or placebo. The primary safety outcome was a composite of major adverse cardiovascular events...
Paper Details
Title
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Published Date
Jan 24, 2019
Volume
380
Issue
4
Pages
347 - 357
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.